论文部分内容阅读
目的观察依达拉奉治疗急性颅脑损伤的临床疗效。方法采用随机双盲对照试验。将连续收治的96例急性颅脑伤患者分依达拉奉治疗组与吡拉西坦对照组各48例进行对照。观察治疗期间不同时期格拉斯哥昏迷评分(GCS),治疗结束后及康复期格拉斯哥预后评分(GOS)。结果依达拉奉治疗组GCS评分在用药7d后开始明显优于对照组(P<0.05),在2周的治疗期结束后GCS评分和4个月后随访进行GOS评分,治疗组明显优于对组(P<0.05)。随访结束后评定病死率,治疗组死亡5例(10.4%),对照组死亡12例(25.0%),显示两组间差异有统计学意义(P<0.05)。结论依达拉奉治疗急性颅脑损伤疗效好,能明显降低病死率,改善预后。
Objective To observe the clinical efficacy of edaravone in the treatment of acute craniocerebral injury. Methods Randomized double-blind control trial. Ninety-six consecutive patients with acute craniocerebral injury were divided into control group (48 cases) and edaravone group (48 cases). Glasgow Coma Scale (GCS), Glasgow Outcome Scale (GOS) at the end of treatment, and recovery period were observed during the treatment period. Results The GCS score of edaravone treatment group was significantly better than that of control group 7 days after treatment (P <0.05). The GCS score at the end of 2 weeks and the GOS score at 4 months follow-up were significantly better Pair group (P <0.05). Mortality was assessed after follow-up, with 5 deaths (10.4%) in the treatment group and 12 (25.0%) deaths in the control group, indicating a statistically significant difference between the two groups (P <0.05). Conclusion Edaravone is effective in treating acute craniocerebral injury, which can significantly reduce the mortality and improve the prognosis.